Preclinical and Clinical Evaluation of Farnesyltransferase Inhibitors

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2003 Feb 14

PMID 12583826

Citations 6

Authors

Charles Baum

Paul Kirschmeier

Affiliations

Soon will be listed here.

Abstract

Farnesylation of Ras, a protooncogene that is frequently mutated in a number of malignancies, is critical for its biologic function. This observation has led to the development of several agents that inhibit farnesyltransferase, known as farnesyltransferase inhibitors (FTIs). The antiproliferative and antitumor effects of these agents have been demonstrated in preclinical and clinical studies. Interestingly, FTI activity does not necessarily rely on ras mutational status, indicating that Ras is not the only FTI target. Clinical data suggest that FTIs, alone and in combination with other agents, have antitumor activity. Further study is needed to determine the precise mechanism of FTI antitumor activity as well as how and where FTIs will be best used clinically.

Citing Articles

Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target.

Kobayashi E, Kondo S, Dochi H, Moriyama-Kita M, Hirai N, Komori T Cancers (Basel). 2022; 14(12).

PMID: 35740492 PMC: 9220992. DOI: 10.3390/cancers14122826.

Ras Isoforms from Lab Benches to Lives-What Are We Missing and How Far Are We?.

Nair A, Kubatzky K, Saha B Int J Mol Sci. 2021; 22(12).

PMID: 34204435 PMC: 8233758. DOI: 10.3390/ijms22126508.

Quantitative determination of geranyl diphosphate levels in cultured human cells.

Holstein S, Tong H, Kuder C, Hohl R Lipids. 2009; 44(11):1055-62.

PMID: 19856009 DOI: 10.1007/s11745-009-3355-x.

Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones.

Porter S, Hildebrandt E, Breevoort S, Mokry D, Dore T, Schmidt W Biochim Biophys Acta. 2007; 1773(6):853-62.

PMID: 17467817 PMC: 1976251. DOI: 10.1016/j.bbamcr.2007.03.004.

Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye J Breast Cancer Res. 2006; 7(6):R1159-67.

PMID: 16457696 PMC: 1410750. DOI: 10.1186/bcr1357.

References

Alsina M, Fonseca R, Wilson E, Belle A, Gerbino E, Price-Troska T . Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004; 103(9):3271-7. DOI: 10.1182/blood-2003-08-2764. View

Le Gouill S, Pellat-Deceunynck C, Harousseau J, Robillard N, Bataille R, Amiot M . Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002; 16(9):1664-7. DOI: 10.1038/sj.leu.2402629. View

Rose W, Lee F, Fairchild C, Lynch M, Monticello T, Kramer R . Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001; 61(20):7507-17. View

Dy G, Bruzek L, Croghan G, Mandrekar S, Erlichman C, Peethambaram P . A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res. 2005; 11(5):1877-83. DOI: 10.1158/1078-0432.CCR-04-1769. View

Ashar H, James L, Gray K, Carr D, Black S, Armstrong L . Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000; 275(39):30451-7. DOI: 10.1074/jbc.M003469200. View

Crespo N, Ohkanda J, Yen T, Hamilton A, Sebti S . The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001; 276(19):16161-7. DOI: 10.1074/jbc.M006213200. View

Sebti S, Hamilton A . Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2001; 19(56):6584-93. DOI: 10.1038/sj.onc.1204146. View

Keely P, Rusyn E, Cox A, Parise L . R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol. 1999; 145(5):1077-88. PMC: 2133135. DOI: 10.1083/jcb.145.5.1077. View

Peters D, Hoover R, GERLACH M, Koh E, Zhang H, Choe K . Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001; 97(5):1404-12. DOI: 10.1182/blood.v97.5.1404. View

10.

Keely P, Westwick J, Whitehead I, Der C, Parise L . Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature. 1997; 390(6660):632-6. DOI: 10.1038/37656. View

11.

Hoover R, Mahon F, Melo J, Daley G . Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002; 100(3):1068-71. DOI: 10.1182/blood.v100.3.1068. View

12.

Adjei A, Mauer A, Bruzek L, Marks R, Hillman S, Geyer S . Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21(9):1760-6. DOI: 10.1200/JCO.2003.09.075. View

13.

Stokoe D, Macdonald S, Cadwallader K, Symons M, Hancock J . Activation of Raf as a result of recruitment to the plasma membrane. Science. 1994; 264(5164):1463-7. DOI: 10.1126/science.7811320. View

14.

Adjei A, Erlichman C, Davis J, Cutler D, Sloan J, Marks R . A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000; 60(7):1871-7. View

15.

Kennedy S, Wagner A, Conzen S, Jordan J, Bellacosa A, Tsichlis P . The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997; 11(6):701-13. DOI: 10.1101/gad.11.6.701. View

16.

Hussein D, Taylor S . Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002; 115(Pt 17):3403-14. DOI: 10.1242/jcs.115.17.3403. View

17.

Petit T, Izbicka E, Lawrence R, Bishop W, Weitman S, Von Hoff D . Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol. 1999; 10(4):449-53. DOI: 10.1023/a:1008313232381. View

18.

Ashar H, James L, Gray K, Carr D, McGuirk M, Maxwell E . The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res. 2000; 262(1):17-27. DOI: 10.1006/excr.2000.5076. View

19.

Kelland L, Smith V, Valenti M, Patterson L, Clarke P, Detre S . Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res. 2001; 7(11):3544-50. View

20.

Brassard D, English J, Malkowski M, Kirschmeier P, Nagabhushan T, Bishop W . Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res. 2002; 273(2):138-46. DOI: 10.1006/excr.2001.5440. View